医学
临床终点
内科学
贝伐单抗
不利影响
临床研究阶段
耐火材料(行星科学)
胃肠病学
结直肠癌
癌症
加药
肿瘤科
临床试验
外科
化疗
物理
天体生物学
作者
Pei Zhang,Xiaofen Li,Xin Wang,Yu Yang,Jianfei Wang,Dan Cao
标识
DOI:10.3389/fimmu.2024.1450533
摘要
The third-line treatment for refractory colorectal cancer (CRC) has limited efficacy. This study aimed to evaluate the safety and efficacy of SHR-8068 (an anti-CTLA-4 antibody), combined with adebrelimab (an anti-PD-L1 antibody), and bevacizumab in refractory non-microsatellite instability-high (MSI-H) or proficient mismatch repair (pMMR) CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI